Liquid Biopsy Disease Framework

Our platform leverages bio-orthogonal chemistry. These are reactions that are highly selective and occur only between specifically designed chemical groups. We target the building blocks of proteins, creating modular protein cross sections (PCS), that provide a quantitative (not relative) digital read out.

Modular protein cross sections (PCS) provide robust signals across bio-fluids, offering novel and complementary insights into biology. In addition to plasma and urine, we are exploring PCS signals in saliva and cells.

Our platform is designed to be highly adaptable, enabling Proteotype to quickly develop new diagnostics for a variety of diseases. In addition to cancer, we have clinical proof of concept in auto-immune and neurodegenerative diseases.

One of the platform’s most powerful features is the speed with which new diagnostics can be designed, only requiring diagnostic samples with paired clinical data.

A wide range of applications: PCS enables the efficient expansion into new indications